Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Creative Style: 10 Architects Reclassifying the Business - 2Man Charged for Stealing ‘Incredibly Precious’ 286-Year-Old Violin, Worth More Than $200,000, from a Tavern
- 3Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- 4Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- 5Mom warns of Christmas gift hazard as daughter recovers in hospital
- Study reveals links between global food systems, obesity, and climate change
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- The Solution to Ecological Protection: Saving Nature for People in the future
- Understanding Various Sorts of Financial balances: An Extensive Outline
- Historical mysteries solved by science in 2025
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- Remarkable Spots for Hot Air Swelling All over The Planet
